Controlled dangerous substances; adding certain substances to Schedules I and IV; effective date.
HB3767 updates Oklahoma’s controlled substances schedules by adding a large number of newly identified or emerging drugs to Schedule I and Schedule IV, including many synthetic opioids, fentanyl analogs, synthetic cannabinoids, benzodiazepine-like substances, and other hallucinogenic or depressant compounds. The bill also revises related definitions under the Anti-Drug Diversion Act and preserves the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control’s authority to exempt certain legitimate industrial or medicinal products from scheduling when abuse potential is reduced or eliminated.
A notable feature of the bill is that it also aligns state law with federal drug scheduling changes for FDA-approved prescription products: if the DEA designates, reschedules, or deletes such a drug under federal law, the product is excluded from Schedule I in Oklahoma unless the State Board of Pharmacy acts otherwise. The bill takes effect November 1, 2026.
The bill amends 63 O.S. 2021 Sections 2-204, 2-210, and 2-309B, expanding the list of controlled dangerous substances and refining the statutory framework used to regulate drug diversion and dispensing. Its practical effect is to broaden criminal and regulatory coverage over a wide range of designer drugs and analogs, while also preserving exemptions for certain industrial uses of chemicals such as GBL, GHV, GVL, and 1,4-butanediol and for OTC or legitimate medicinal products. It affects law enforcement, pharmacists, prescribers, manufacturers, distributors, and other registrants subject to Oklahoma’s controlled substances and anti-diversion laws.
The bill appears to have been broadly supported and moved through the Legislature with strong bipartisan margins, including unanimous committee votes in the House Criminal Judiciary Committee, House Judiciary and Public Safety Oversight Committee, and Senate Health & Human Services Committee, and overwhelming floor votes in both chambers. The available transcript snippets are procedural and do not show substantive opposition, suggesting the measure was treated as a technical/public-safety update rather than a controversial policy shift.
The main policy tension in the bill is between expanding drug-control authority to cover new synthetic and designer substances and preserving exemptions for legitimate industrial, commercial, and medical uses. The bill specifically allows the Bureau to exempt products containing certain chemicals if they are labeled and marketed for legitimate use and reduces abuse potential, which reflects concern from manufacturers and other lawful users about overbroad scheduling. Another point of possible contention is the breadth and complexity of the added substance lists, which may raise implementation and compliance concerns for pharmacists, dispensers, and regulated businesses even though the legislative record shows little recorded opposition.